Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

OBJECTIVE: Low disease activity (LDA) and remission are emerging treat-to-target (T2T) endpoints in SLE. However, the rates at which these endpoints are met in patients with high disease activity (HDA) are unknown. Atacicept, which targets B lymphocyte stimulator and a proliferation-inducing ligand,...

Descripción completa

Detalles Bibliográficos
Autores principales: Morand, Eric F, Isenberg, David A, Wallace, Daniel J, Kao, Amy H, Vazquez-Mateo, Cristina, Chang, Peter, Pudota, Kishore, Aranow, Cynthia, Merrill, Joan T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516108/
https://www.ncbi.nlm.nih.gov/pubmed/32107560
http://dx.doi.org/10.1093/rheumatology/keaa029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516108/
https://www.ncbi.nlm.nih.gov/pubmed/32107560
http://dx.doi.org/10.1093/rheumatology/keaa029

Ejemplares similares